NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.74 +1.33 (+9.23 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$14.81
Today's Range$14.70 - $15.91
52-Week Range$11.72 - $20.15
Volume860 shs
Average Volume87,419 shs
Market Capitalization$507.49 million
P/E Ratio-1.87
Dividend YieldN/A
Clementia Pharmaceuticals logoClementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Receive CMTA News and Ratings via Email

Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio7.06
Quick Ratio7.06


Trailing P/E Ratio-1.87
Forward P/E Ratio-8.89
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.47 per share
Price / Book3.52


EPS (Most Recent Fiscal Year)($7.93)
Net Income$-115,450,000.00
Net MarginsN/A
Return on Equity-165.55%
Return on Assets-71.97%


Outstanding Shares31,720,000

Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions

What is Clementia Pharmaceuticals' stock symbol?

Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."

How were Clementia Pharmaceuticals' earnings last quarter?

Clementia Pharmaceuticals Inc (NASDAQ:CMTA) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.42) EPS for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.09. View Clementia Pharmaceuticals' Earnings History.

When is Clementia Pharmaceuticals' next earnings date?

Clementia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Clementia Pharmaceuticals.

What price target have analysts set for CMTA?

5 analysts have issued twelve-month price targets for Clementia Pharmaceuticals' stock. Their predictions range from $23.00 to $32.00. On average, they anticipate Clementia Pharmaceuticals' stock price to reach $26.60 in the next twelve months. View Analyst Ratings for Clementia Pharmaceuticals.

Who are some of Clementia Pharmaceuticals' key competitors?

Who are Clementia Pharmaceuticals' key executives?

Clementia Pharmaceuticals' management team includes the folowing people:
  • Dr. Clarissa Desjardins, Founder, Pres, CEO & Director (Age 51)
  • Mr. Michael Singer, CFO & Corp. Sec. (Age 53)
  • Dr. Donna Roy Grogan M.D., Chief Medical Officer (Age 61)
  • Mr. Jeffery Packman, Chief Devel. Officer (Age 51)
  • Mr. Eric Grinstead, Chief Commercial Officer (Age 61)

When did Clementia Pharmaceuticals IPO?

(CMTA) raised $101 million in an initial public offering (IPO) on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and Leerink Partners served as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

Has Clementia Pharmaceuticals been receiving favorable news coverage?

Press coverage about CMTA stock has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Clementia Pharmaceuticals earned a news impact score of 0.03 on Accern's scale. They also assigned media coverage about the company an impact score of 43.84 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Clementia Pharmaceuticals' major shareholders?

Clementia Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (2.35%), Sphera Funds Management LTD. (0.63%), Artal Group S.A. (0.63%), DAFNA Capital Management LLC (0.33%), Alps Advisors Inc. (0.13%) and Birchview Capital LP (0.12%). View Institutional Ownership Trends for Clementia Pharmaceuticals.

Which major investors are buying Clementia Pharmaceuticals stock?

CMTA stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., DAFNA Capital Management LLC, JPMorgan Chase & Co., Sphera Funds Management LTD., Birchview Capital LP, A.R.T. Advisors LLC and Alps Advisors Inc.. View Insider Buying and Selling for Clementia Pharmaceuticals.

How do I buy shares of Clementia Pharmaceuticals?

Shares of CMTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clementia Pharmaceuticals' stock price today?

One share of CMTA stock can currently be purchased for approximately $15.74.

How big of a company is Clementia Pharmaceuticals?

Clementia Pharmaceuticals has a market capitalization of $507.49 million. The company earns $-115,450,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.

How can I contact Clementia Pharmaceuticals?

Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected]

MarketBeat Community Rating for Clementia Pharmaceuticals (CMTA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  191
MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.